Altimmune rises after GLP-1 drug shows benefits in liver disease study

Shares of Altimmune ALT.O rise 5.9% to $5.33 premarket

The drug developer says its experimental GLP-1 drug improved signs of liver scarring and liver health after 48 weeks of treatment in a mid-stage study of patients with fatty liver disease called MASH

People on pemvidutide's higher dose of 1.8mg lost an average of 7.5% of their body weight at 48 weeks

Up to last close, stock had fallen 30% YTD